Download PDF
Horm Metab Res 2007; 39(10): 710-716
DOI: 10.1055/s-2007-985897
Review

© Georg Thieme Verlag KG Stuttgart · New York

Resistin- and Obesity-associated Metabolic Diseases

M. A. Lazar 1
  • 1Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and The Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, USA
Further Information

Publication History

received 16.10.2006

accepted 01.02.2007

Publication Date:
22 October 2007 (online)

Also available at
   Permissions and Reprints

Abstract

The link between obesity and diabetes is strong as well as complex. Fat cells produce many circulating regulators of insulin sensitivity, including pro-inflammatory cytokines. In rodents, resistin is produced by adipose tissue, and is a significant regulator of glucose metabolism and insulin sensitivity. In humans, resistin is derived made mainly from macrophages. Given the emerging interrelationship between inflammation and metabolic disease, hyperresistinemia may be a biomarker, and/or a mediator, of metabolic and inflammatory diseases in humans as well as in rodents.

Key words

obesity - insulin resistance - resistin - adipokine

References

  • 1 Nathan DM. Long-term complications of diabetes mellitus.  New Eng J Med. 1993;  328 1676-1685
    CrossrefPubMedGoogle Scholar
  • 2 Crofford OB. Diabetes control and complications.  Ann Rev Med. 1995;  46 267-279
    CrossrefPubMedGoogle Scholar
  • 3 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.  JAMA. 2003;  289 76-79
    CrossrefPubMedGoogle Scholar
  • 4 Dietz WH. Overweight in childhood and adolescence.  N Engl J Med. 2004;  350 855-857
    CrossrefPubMedGoogle Scholar
  • 5 Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002.  Diabetes Care. 2003;  26 917-932
    CrossrefPubMedGoogle Scholar
  • 6 Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States.  JAMA. 2003;  290 1884-1890
    CrossrefPubMedGoogle Scholar
  • 7 Kahn CR, Vicent D, Doria A. Genetics of non-insulin-dependent (type II) diabetes mellitus.  Ann Rev Med. 1996;  47 509-531
    CrossrefPubMedGoogle Scholar
  • 8 Kamin D, Hadigan C, Lehrke M, Mazza S, Lazar MA, Grinspoon S. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone.  J Clin Endocrinol Metab. 2005;  90 3423-3426
    CrossrefPubMedGoogle Scholar
  • 9 Ahima RS, Flier JS. Adipose tissue as an endocrine organ.  Trends Endocrinol Metab. 2000;  11 327-332
    PubMedGoogle Scholar
  • 10 Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance.  Trends Endocrinol Metab. 2002;  13 18-23
    CrossrefPubMedGoogle Scholar
  • 11 Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.  Diabetes. 1997;  46 1-10
    PubMedGoogle Scholar
  • 12 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ.  J Clin Endocrinol Metab. 2004;  89 2548-2556
    CrossrefPubMedGoogle Scholar
  • 13 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432
    CrossrefPubMedGoogle Scholar
  • 14 Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.  Nature. 1999;  401 73-76
    CrossrefPubMedGoogle Scholar
  • 15 Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, Paoli AM De, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy.  N Engl J Med. 2002;  346 570-578
    CrossrefPubMedGoogle Scholar
  • 16 Ahima RS, Flier JS. Leptin.  Annu Rev Physiol. 2000;  62 413-437
    CrossrefPubMedGoogle Scholar
  • 17 Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome.  J Intern Med. 2005;  257 167-175
    CrossrefPubMedGoogle Scholar
  • 18 Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes.  Nature. 2001;  409 307-312
    CrossrefPubMedGoogle Scholar
  • 19 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation.  N Engl J Med. 1999;  340 448-454
    CrossrefPubMedGoogle Scholar
  • 20 Shi H, Tzameli I, Bjorbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling.  J Biol Chem. 2004;  279 34733-34740
    CrossrefPubMedGoogle Scholar
  • 21 Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance.  Int J Obes Relat Metab Disord. 2003;  27 ((Suppl 3)) S49-S52
    CrossrefPubMedGoogle Scholar
  • 22 Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes.  J Clin Invest. 2005;  115 1111-1119
    Google Scholar
  • 23 White MF. Insulin signaling in health and disease.  Science. 2003;  302 1710-1711
    CrossrefPubMedGoogle Scholar
  • 24 Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.  Nature. 2005;  436 356-362
    CrossrefPubMedGoogle Scholar
  • 25 Kuenzli S, Tran C, Saurat JH. Retinoid receptors in inflammatory responses: a potential target for pharmacology.  Curr Drug Targets Inflamm Allergy. 2004;  3 355-360
    CrossrefPubMedGoogle Scholar
  • 26 Samal B, Sun Y, Stearns G, Xie C, Suggs S, MacNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.  Mol Cell Biol. 1994;  14 1431-1437
    CrossrefPubMedGoogle Scholar
  • 27 Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.  Science. 2005;  307 426-430
    CrossrefPubMedGoogle Scholar
  • 28 Lehrke M, Lazar MA. Inflamed about obesity.  Nat Med. 2004;  10 126-127
    PubMedGoogle Scholar
  • 29 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.  J Clin Invest. 2003;  112 1821-1830
    CrossrefPubMedGoogle Scholar
  • 30 Weisberg SP, MacCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante  Jr  AW. Obesity is associated with macrophage accumulation in adipose tissue.  J Clin Invest. 2003;  112 1796-1808
    CrossrefPubMedGoogle Scholar
  • 31 Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting.  Diabetes. 2004;  53 1671-1679
    CrossrefPubMedGoogle Scholar
  • 32 Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiya T, Niiya T, Shimizu I, Nishida W, Hashiramoto M, Kanatsuka A, Fujii Y, Ohashi J, Makino H. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3.  Am J Hum Genet. 2004;  75 678-686
    CrossrefPubMedGoogle Scholar
  • 33 Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL. Insulin resistance and substrate utilization in human endotoxemia.  J Clin Endocrinol Metab. 2000;  85 3770-3778
    CrossrefPubMedGoogle Scholar
  • 34 Berghe G Van den. How does blood glucose control with insulin save lives in intensive care?.  J Clin Invest. 2004;  114 1187-1195
    CrossrefPubMedGoogle Scholar
  • 35 Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.  Science. 2001;  293 1673-1677
    CrossrefPubMedGoogle Scholar
  • 36 Fernandez-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness.  Diabetologia. 1999;  42 1367-1374
    CrossrefPubMedGoogle Scholar
  • 37 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear peroxisome proliferator-activated receptor γ (PPARγ).  J Biol Chem. 1995;  270 12953-12956
    CrossrefPubMedGoogle Scholar
  • 38 Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor γ (PPARγ): Adipose predominant expression and induction early in adipocyte differentiation.  Endocrinology. 1994;  135 798-800
    CrossrefPubMedGoogle Scholar
  • 39 Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: tissue-specific regulator of an adipocyte enhancer.  Genes Dev. 1994;  8 1224-1234
    PubMedGoogle Scholar
  • 40 Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.  J Clin Invest. 2000;  106 1221-1228
    CrossrefPubMedGoogle Scholar
  • 41 Pajvani UB, Trujillo ME, Combs TP, Iyengar P, Jelicks L, Roth KA, Kitsis RN, Scherer PE. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy.  Nat Med. 2005;  11 797-803
    PubMedGoogle Scholar
  • 42 Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.  J Clin Invest. 2003;  112 608-618
    CrossrefPubMedGoogle Scholar
  • 43 Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.  Trends Pharmacol Sci. 2004;  25 331-336
    CrossrefPubMedGoogle Scholar
  • 44 Martin G, Schoonjans K, Staels B, Auwerx J. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes.  Atherosclerosis. 1998;  137 ((Suppl)) S75-S80
    CrossrefPubMedGoogle Scholar
  • 45 Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents.  Nat Med. 2002;  8 1122-1128
    CrossrefPubMedGoogle Scholar
  • 46 Tordjman J, Chauvet G, Quette J, Beale EG, Forest C, Antoine B. Thiazolidinediones block Fatty Acid release by inducing glyceroneogenesis in fat cells.  J Biol Chem. 2003;  278 18785-18790
    CrossrefPubMedGoogle Scholar
  • 47 Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones.  Diabetes. 1998;  47 691-695
    CrossrefPubMedGoogle Scholar
  • 48 Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.  Diabetes. 2001;  50 2094-2099
    CrossrefPubMedGoogle Scholar
  • 49 Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance.  J Biol Chem. 2001;  276 41245-41254
    CrossrefPubMedGoogle Scholar
  • 50 Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.  Proc Natl Acad Sci USA. 1996;  93 5793-5796
    CrossrefPubMedGoogle Scholar
  • 51 DeVos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.  J Clin Invest. 1996;  98 1004-1009
    PubMedGoogle Scholar
  • 52 Haugen F, Jorgensen A, Drevon CA, Trayhurn P. Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes.  FEBS Lett. 2001;  507 105-108
    CrossrefPubMedGoogle Scholar
  • 53 Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through activation of PPARγ.  Cell. 1998;  93 229-240
    CrossrefPubMedGoogle Scholar
  • 54 Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL.  Cell. 1998;  93 241-252
    CrossrefPubMedGoogle Scholar
  • 55 Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-g is a negative regulator of macrophage activation.  Nature. 1998;  391 79-82
    CrossrefPubMedGoogle Scholar
  • 56 Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the nitric oxide synthase gene.  Mol. Cell. Biol.. 2000;  20 4699-4707
    CrossrefPubMedGoogle Scholar
  • 57 Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators.  Biochem Biophys Res Commun. 2003;  300 472-476
    CrossrefPubMedGoogle Scholar
  • 58 Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans.  PLoS Med. 2004;  1 e45
    CrossrefPubMedGoogle Scholar
  • 59 Jung HS, Youn BS, Cho YM, Yu KY, Park HJ, Shin CS, Kim SY, Lee HK, Park KS. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.  Metabolism. 2005;  54 314-320
    CrossrefPubMedGoogle Scholar
  • 60 Kamin D, Hadigan C, Lehrke M, Mazza S, Lazar MA, Grinspoon S. Resistin levels in HIV-infected patients with lipoatrophy decrease in response to rosiglitazone.  J Clin Endocrinol Metab. 2005;  90 3423-3426
    CrossrefPubMedGoogle Scholar
  • 61 Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.  Diabetologia. 2001;  44 2210-2219
    CrossrefPubMedGoogle Scholar
  • 62 Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production.  J Clin Invest. 2003;  111 225-230
    CrossrefPubMedGoogle Scholar
  • 63 Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats.  J Clin Invest. 2004;  114 224-231
    CrossrefPubMedGoogle Scholar
  • 64 Pravenec M, Kazdova L, Landa V, Zidek V, Mlejnek P, Jansa P, Wang J, Qi N, Kurtz TW. Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat.  J Biol Chem. 2003;  278 45209-45215
    CrossrefPubMedGoogle Scholar
  • 65 Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA. Abnormal glucose homeostasis due to chronic hyperresistinemia.  Diabetes. 2004;  53 1937-1941
    PubMedGoogle Scholar
  • 66 Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA. Regulation of fasted blood glucose by resistin.  Science. 2004;  303 1195-1198
    CrossrefPubMedGoogle Scholar
  • 67 Muse ED, Obici S, Bhanot S, Monia BP, MacKay RA, Rajala MW, Scherer PE, Rossetti L. Role of resistin in diet-induced hepatic insulin resistance.  J Clin Invest. 2004;  114 232-239
    PubMedGoogle Scholar
  • 68 Kim KH, Zhao L, Moon Y, Kang C, Sul HS. Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity.  Proc Natl Acad Sci USA. 2004;  101 6780-6785
    CrossrefPubMedGoogle Scholar
  • 69 Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, FV Peale J, Shelton DL, Hebert CC. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family.  EMBO J. 2000;  19 4046-4055
    CrossrefPubMedGoogle Scholar
  • 70 Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GD, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules.  Proc Natl Acad Sci USA. 2001;  98 502-506
    CrossrefPubMedGoogle Scholar
  • 71 Banerjee RR, Lazar MA. Dimerization of resistin and resistin-like molecules is determined by a single cysteine.  J Biol Chem. 2001;  276 25970-25973
    CrossrefPubMedGoogle Scholar
  • 72 Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones.  Science. 2004;  304 1154-1158
    CrossrefPubMedGoogle Scholar
  • 73 Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA. Activation of SOCS-3 by resistin.  Mol Cell Biol. 2005;  25 1569-1575
    CrossrefPubMedGoogle Scholar
  • 74 Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease.  J Surg Res. 2005;  126 121-129
    CrossrefPubMedGoogle Scholar
  • 75 Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction.  Circulation. 2003;  108 736-740
    CrossrefPubMedGoogle Scholar
  • 76 Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions.  Biochem Biophys Res Commun. 2004;  314 415-419
    CrossrefPubMedGoogle Scholar
  • 77 Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways.  Circulation. 2004;  110 3335-3340
    CrossrefPubMedGoogle Scholar
  • 78 Axelsson J, Heimburger O, Lindholm B, Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines.  J Ren Nutr. 2005;  15 131-136
    CrossrefPubMedGoogle Scholar
  • 79 Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M, Nakamura H, Ohsuzu F. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease.  J Am Coll Cardiol. 2005;  46 379-380
    CrossrefPubMedGoogle Scholar
  • 80 Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans.  Circulation. 2005;  111 932-939
    CrossrefPubMedGoogle Scholar
  • 81 Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, Devaney JM, Fishman C, Stamou S, Canos D, Zbinden S, Clavijo LC, Jang GJ, Andrews JA, Zhu J, Epstein SE. The potential role of resistin in atherogenesis.  Atherosclerosis. 2005;  182 241-248
    CrossrefPubMedGoogle Scholar
  • 82 Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes.  Am J Physiol. 1999;  277 E1-E10
    PubMedGoogle Scholar
  • 83 Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes.  J Biol Chem. 2003;  278 13740-13746
    CrossrefPubMedGoogle Scholar
  • 84 Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2.  J Biol Chem. 2002;  277 42394-42398
    CrossrefPubMedGoogle Scholar
  • 85 Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Obberghen E Van. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice.  J Biol Chem. 2001;  276 47944-47949
    PubMedGoogle Scholar
  • 86 Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse.  Proc Natl Acad Sci USA. 2004;  101 10422-10427
    CrossrefPubMedGoogle Scholar
  • 87 Graveleau C, Zaha VG, Mohajer A, Banerjee RR, Dudley-Rucker N, Steppan CM, Rajala MW, Scherer PE, Ahima RS, Lazar MA, Abel ED. Mouse and human resistin impair glucose transport in primary mouse cardiomyocytes and oligomerization is required for this biological action.  J Biol Chem. 2005;  280 31679-31685
    CrossrefPubMedGoogle Scholar
  • 88 Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.  Nature. 2003;  423 762-769
    CrossrefPubMedGoogle Scholar
  • 89 Yang RZ, Huang Q, Xu A, MacLenithan JC, Eisen JA, Shuldiner AR, Alkan S, Gong DW. Comparative studies of resistin expression and phylogenomics in human and mouse.  Biochem Biophys Res Commun. 2003;  310 927-935
    CrossrefPubMedGoogle Scholar
  • 90 Seo JB, Noh MJ, Yoo EJ, Park SY, Park J, Lee IK, Park SD, Kim JB. Functional characterization of the human resistin promoter with adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element binding protein 1c and CCAAT enhancer binding protein-alpha.  Mol Endocrinol. 2003;  17 1522-1533
    CrossrefPubMedGoogle Scholar
  • 91 Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway.  Biochem Biophys Res Commun. 2005;  334 1092-1101
    CrossrefPubMedGoogle Scholar
  • 92 MacTernan CL, MacTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes.  Lancet. 2002;  359 46-47
    CrossrefPubMedGoogle Scholar
  • 93 Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans.  Diabetes. 2001;  50 2199-2202
    CrossrefPubMedGoogle Scholar
  • 94 Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties.  J Immunol. 2005;  174 5789-5795
    CrossrefPubMedGoogle Scholar
  • 95 Gerber M, Boettner A, Seidel B, Lammert A, Bar J, Schuster E, Thiery J, Kiess W, Kratzsch J. Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance.  J Clin Endocrinol Metab. 2005;  90 4503-4509
    CrossrefPubMedGoogle Scholar
  • 96 Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: Relationship to anthropometric and metabolic parameters.  Metabolism. 2005;  54 471-475
    CrossrefPubMedGoogle Scholar
  • 97 Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance.  Clin Lab. 2003;  49 571-576
    PubMedGoogle Scholar
  • 98 Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects.  J Clin Endocrinol Metab. 2003;  88 4848-4856
    CrossrefPubMedGoogle Scholar
  • 99 Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease.  Am J Kidney Dis. 2003;  42 62-66
    CrossrefPubMedGoogle Scholar
  • 100 Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, Pagano GF. Relationships between human serum resistin, inflammatory markers and insulin resistance.  Int J Obes Relat Metab Disord. 2005;  29 1315-1320
    CrossrefPubMedGoogle Scholar
  • 101 Hasegawa G, Ohta M, Ichida Y, Obayashi H, Shigeta M, Yamasaki M, Fukui M, Yoshikawa T, Nakamura N. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity.  Acta Diabetol. 2005;  42 104-109
    CrossrefPubMedGoogle Scholar
  • 102 Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, Bertelli M, Fanin E, Andrighetto G, Federspil G, Vettor R. Increased serum resistin in adults with prader-willi syndrome is related to obesity and not to insulin resistance.  J Clin Endocrinol Metab. 2005;  90 4335-4340
    CrossrefPubMedGoogle Scholar
  • 103 Kunnari A, Ukkola O, Kesaniemi YA. Resistin polymorphisms are associated with cerebrovascular disease in Finnish Type 2 diabetic patients.  Diabet Med. 2005;  22 583-589
    CrossrefPubMedGoogle Scholar
  • 104 Harsch IA, Koebnick C, Wallaschofski H, Schahin SP, Hahn EG, Ficker JH, Lohmann T, Konturek PC. Resistin levels in patients with obstructive sleep apnoea syndrome-the link to subclinical inflammation?.  Med Sci Monit. 2004;  10 CR510-515
    PubMedGoogle Scholar
  • 105 Azuma K, Oguchi S, Matsubara Y, Mamizuka T, Murata M, Kikuchi H, Watanabe K, Katsukawa F, Yamazaki H, Shimada A, Saruta T. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals.  Horm Metab Res. 2004;  36 564-570
    Article in Thieme ConnectPubMedGoogle Scholar
  • 106 Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Ri . Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity.  Obes Res. 2004;  12 962-971
    CrossrefPubMedGoogle Scholar
  • 107 Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians.  Diabetes. 2004;  53 1279-1284
    CrossrefPubMedGoogle Scholar
  • 108 Silha JV, Murphy LJ. Serum resistin (FIZZ3) protein is increased in obese humans.  J Clin Endocrinol Metab. 2004;  89 1977 , authors' reply 1977-1978
    PubMedGoogle Scholar
  • 109 Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects.  J Clin Endocrinol Metab. 2004;  89 1844-1848
    CrossrefPubMedGoogle Scholar
  • 110 Valsamakis G, MacTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, Kumar S. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.  Metabolism. 2004;  53 430-434
    CrossrefPubMedGoogle Scholar
  • 111 Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK, Park KS. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2004;  89 150-156
    CrossrefPubMedGoogle Scholar
  • 112 Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes.  Clin Chim Acta. 2004;  339 57-63
    CrossrefPubMedGoogle Scholar
  • 113 MacTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, MacTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.  J Clin Endocrinol Metab. 2003;  88 6098-6106
    CrossrefPubMedGoogle Scholar
  • 114 Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans.  J Clin Endocrinol Metab. 2003;  88 5452-5455
    CrossrefPubMedGoogle Scholar
  • 115 Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals.  Obes Res. 2003;  11 997-1001
    CrossrefPubMedGoogle Scholar
  • 116 Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.  J Biol Chem. 2004;  279 12152-12162
    CrossrefPubMedGoogle Scholar
  • 117 Diez JJ, Iglesias P, Fernandez-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, Codoceo R, Selgas R. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease.  Clin Endocrinol (Oxf). 2005;  62 242-249
    CrossrefPubMedGoogle Scholar
  • 118 Al-Daghri ND, Chetty RD, MacTernan Pg PD, Al-Rubeaan KD, OP OA-A, Jones AD, Kumar SP. Serum resistin is associated with C - reactive protein & LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population.  Cardiovasc Diabetol. 2005;  4 10
    CrossrefPubMedGoogle Scholar
  • 119 Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.  Diabetes Care. 2004;  27 2450-2457
    CrossrefPubMedGoogle Scholar
  • 120 Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro.  Biochem Biophys Res Commun. 2003;  309 286-290
    CrossrefPubMedGoogle Scholar
  • 121 Xita N, Georgiou I, Tsatsoulis A, Kourtis A, Kukuvitis A, Panidis D. A polymorphism in the resistin gene promoter is associated with body mass index in women with polycystic ovary syndrome.  Fertil Steril. 2004;  82 1466-1467
    CrossrefPubMedGoogle Scholar
  • 122 Conneely KN, Silander K, Scott LJ, Mohlke KL, Lazaridis KN, Valle TT, Tuomilehto J, Bergman RN, Watanabe RM, Buchanan TA, Collins FS, Boehnke M. Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects.  Diabetologia. 2004;  47 1782-1788
    CrossrefPubMedGoogle Scholar
  • 123 Mattevi VS, Zembrzuski VM, Hutz MH. A resistin gene polymorphism is associated with body mass index in women.  Hum Genet. 2004;  115 208-212
    PubMedGoogle Scholar
  • 124 Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance.  Diabetes. 2003;  52 1611-1618
    PubMedGoogle Scholar
  • 125 Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians.  J Clin Endocrinol Metab. 2002;  87 2520-2524
    CrossrefPubMedGoogle Scholar
  • 126 Engert JC, Vohl MC, Williams SM, Lepage P, Loredo-Osti JC, Faith J, Dore C, Renaud Y, Burtt NP, Villeneuve A, Hirschhorn JN, Altshuler D, Groop LC, Despres JP, Gaudet D, Hudson TJ. 5' flanking variants of resistin are associated with obesity.  Diabetes. 2002;  51 1629-1634
    PubMedGoogle Scholar
  • 127 Chung SS, Choi HH, Kim KW, Cho YM, Lee HK, Park KS. Regulation of human resistin gene expression in cell systems: an important role of stimulatory protein 1 interaction with a common promoter polymorphic site.  Diabetologia. 2005;  48 1150-1158
    CrossrefPubMedGoogle Scholar
  • 128 Cho YM, Youn BS, Chung SS, Kim KW, Lee HK, Yu KY, Park HJ, Shin HD, Park KS. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans.  Diabetologia. 2004;  47 559-565
    PubMedGoogle Scholar

Correspondence

M. A. Lazar

Division of Endocrinology

Diabetes and Metabolism

Department of Medicine and The Institute for Diabetes

Obesity and Metabolism

University of Pennsylvania School of Medicine

19104-6149 Philadelphia

USA

Phone: +1/215/898 01 98

Fax: +2/215/898 54 08

Email: lazar@mail.med.upenn.edu